Arterial hypertension is an established cardiovascular risk factor [1], while antihypertensive therapy is associated with substantial cardiovascular benefits [2]. Therefore, research in the field of hypertension has moved to more expanded boundaries, aiming to address whether aggressive blood pressure reduction is superior to the conservative one. Several randomized trials have been conducted in the past without definite conclusions (probably due to inadequate numbers of participants), while in the last decade three large studies (ACCORD, SPS3, and SPRINT) [3–5] yielded contradictory findings.
